Salem Investment Counselors Inc. Grows Stake in Astera Labs, Inc. $ALAB

Salem Investment Counselors Inc. raised its position in Astera Labs, Inc. (NASDAQ:ALAB) by 4.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 183,728 shares of the company’s stock after acquiring an additional 7,884 shares during the quarter. Astera Labs makes up 1.0% of Salem Investment Counselors Inc.’s portfolio, making the stock its 19th biggest holding. Salem Investment Counselors Inc.’s holdings in Astera Labs were worth $35,974,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Astera Labs during the 2nd quarter valued at about $29,000. Bernard Wealth Management Corp. bought a new stake in Astera Labs during the second quarter valued at approximately $36,000. Clearstead Trust LLC increased its holdings in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after buying an additional 461 shares during the last quarter. Advisors Asset Management Inc. raised its position in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after acquiring an additional 194 shares during the period. Finally, Manchester Capital Management LLC boosted its stake in shares of Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after acquiring an additional 283 shares during the last quarter. 60.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALAB has been the subject of several analyst reports. Morgan Stanley restated an “overweight” rating and issued a $210.00 price objective on shares of Astera Labs in a research note on Wednesday, December 3rd. Citigroup reaffirmed an “outperform” rating on shares of Astera Labs in a research note on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft boosted their price objective on Astera Labs from $160.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. BNP Paribas Exane began coverage on shares of Astera Labs in a research note on Thursday, November 20th. They set an “outperform” rating and a $225.00 target price on the stock. Finally, Cowen reiterated a “hold” rating on shares of Astera Labs in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Astera Labs has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Astera Labs Stock Performance

ALAB opened at $144.94 on Wednesday. The stock has a market capitalization of $24.48 billion, a price-to-earnings ratio of 130.58, a PEG ratio of 2.68 and a beta of 1.51. The company has a fifty day moving average of $163.73 and a 200 day moving average of $154.73. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.39 by $0.10. The business had revenue of $230.58 million during the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The business’s revenue was up 103.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. On average, equities research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Insider Activity at Astera Labs

In other Astera Labs news, COO Sanjay Gajendra sold 90,459 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $13,088,512.71. Following the completion of the transaction, the chief operating officer owned 1,599,750 shares in the company, valued at $231,467,827.50. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $192.16, for a total value of $1,921,600.00. Following the completion of the sale, the general counsel directly owned 151,573 shares in the company, valued at approximately $29,126,267.68. The trade was a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 586,936 shares of company stock valued at $89,331,140 in the last 90 days. 12.50% of the stock is currently owned by insiders.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.